Mersana Therapeutics Inc. [NASDAQ: MRSN] slipped around -0.93 points on Thursday, while shares priced at $19.06 at the close of the session, down -4.65%. Mersana Therapeutics Inc. stock is now 232.64% up from its year-to-date (YTD) trading value. MRSN Stock saw the intraday high of $20.39 and lowest of $18.80 per share. The company’s 52-week high price is 23.40, which means current price is +362.62% above from all time high which was touched on 05/29/20.
Compared to the average trading volume of 2.13M shares, MRSN reached a trading volume of 1358908 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Mersana Therapeutics Inc. [MRSN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRSN shares is $21.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRSN stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for Mersana Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 29, 2020. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $7 to $12. The new note on the price target was released on January 21, 2020, representing the official price target for Mersana Therapeutics Inc. stock.
The Average True Range (ATR) for Mersana Therapeutics Inc. is set at 1.66, with the Price to Sales ratio for MRSN stock in the period of the last 12 months amounting to 1152.26. The Price to Book ratio for the last quarter was 14.55, with the Price to Cash per share for the same quarter was set at 1.18.
How has MRSN stock performed recently?
Mersana Therapeutics Inc. [MRSN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.44. With this latest performance, MRSN shares gained by 87.05% in over the last four-week period, additionally plugging by 378.29% over the last 6 months – not to mention a rise of 350.59% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRSN stock in for the last two-week period is set at 64.95, with the RSI for the last a single of trading hit 60.70, and the three-weeks RSI is set at 66.38 for Mersana Therapeutics Inc. [MRSN]. The present Moving Average for the last 50 days of trading for this stock 11.62, while it was recorded at 19.89 for the last single week of trading, and 6.25 for the last 200 days.
Mersana Therapeutics Inc. [MRSN]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Mersana Therapeutics Inc. [MRSN] shares currently have an operating margin of -71.69. Mersana Therapeutics Inc.’s Net Margin is presently recorded at -66.97.
Return on Total Capital for MRSN is now -63.42, given the latest momentum, and Return on Invested Capital for the company is -61.14. Return on Equity for this stock declined to -64.76, with Return on Assets sitting at -30.32. When it comes to the capital structure of this company, Mersana Therapeutics Inc. [MRSN] has a Total Debt to Total Equity ratio set at 10.38. Additionally, MRSN Total Debt to Total Capital is recorded at 9.40, with Total Debt to Total Assets ending up at 7.56. Long-Term Debt to Equity for the company is recorded at 6.58, with the Long-Term Debt to Total Capital now at 5.96.
Reflecting on the efficiency of the workforce at the company, Mersana Therapeutics Inc. [MRSN] managed to generate an average of -$339,855 per employee. Receivables Turnover for the company is 183.54 with a Total Asset Turnover recorded at a value of 0.45.Mersana Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.60 and a Current Ratio set at 4.60.
Earnings analysis for Mersana Therapeutics Inc. [MRSN]
With the latest financial reports released by the company, Mersana Therapeutics Inc. posted -0.36/share EPS, while the average EPS was predicted by analysts to be reported at -0.38/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 5.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRSN.
Insider trade positions for Mersana Therapeutics Inc. [MRSN]
There are presently around $852 million, or 61.90% of MRSN stock, in the hands of institutional investors. The top three institutional holders of MRSN stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 11,963,649, which is approximately 0% of the company’s market cap and around 0.80% of the total institutional ownership; SARISSA CAPITAL MANAGEMENT LP, holding 3,750,000 shares of the stock with an approximate value of $74.96 million in MRSN stocks shares; and BLACKROCK INC., currently with $65.7 million in MRSN stock with ownership of nearly 33.308% of the company’s market capitalization.
Positions in Mersana Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 61 institutional holders increased their position in Mersana Therapeutics Inc. [NASDAQ:MRSN] by around 11,926,657 shares. Additionally, 23 investors decreased positions by around 2,292,166 shares, while 11 investors held positions by with 28,384,794 shares. The mentioned changes placed institutional holdings at 42,603,617 shares, according to the latest SEC report filing. MRSN stock had 27 new institutional investments in for a total of 7,161,206 shares, while 10 institutional investors sold positions of 658,505 shares during the same period.